Title: A global study to assess the effects of durvalumab with oleclumab or durvalumab with monalizumab following concurrent chemoradiation in patients with stage III unresectable non-small cell lung cancer (PACIFIC-9)
Study Director: AstraZeneca Clinical Study Information Center
Description: Researchers are conducting a double-blind, placebo-controlled, phase 3 trial to assess the efficacy and safety of durvalumab in combination with oleclumab or monalizumab in patients with locally advanced, unresectable non-small cell lung cancer (NSCLC), who did not progress after platinum-based concurrent chemoradiotherapy (CRT).
Continue Reading
In this 3-arm study, patients with NSCLC will be randomly assigned to receive durvalumab in combination with oleclumab, monalizumab, or placebo.
The primary outcome is progression-free survival. Key secondary endpoints include overall survival, objective response rate, and duration of response.
To be eligible for this study, patients must have histologically- or cytologically-documented NSCLC and must have been treated with concurrent CRT for locally advanced, unresectable stage III disease. For a complete list of eligibility criteria, please refer to the reference.
Status: Recruiting
This study is sponsored by AstraZeneca.
Reference
A global study to assess the effects of durvalumab with oleclumab or durvalumab with monalizumab following concurrent chemoradiation in patients with stage III unresectable non-small cell lung cancer (PACIFIC-9). ClinicalTrials.gov Identifier: NCT05221840. Updated February 24, 2022. Accessed March 22, 2022. https://clinicaltrials.gov/ct2/show/NCT05221840
